The FBXO4 tumor suppressor functions as a barrier to BrafV600E_dependent metastatic melanoma

Eric Lee,Zhaorui Lian,Kurt D'Andre,Richard Letrero,Weiqi Sheng,Shujing Liu,J. Nathaniel Diehl,Dariusz Pytel,Olena Barbash,Lynn M. Schuchter,Ravi Amaravaradi,Xiaowei Xu,Meenhard F. Herlyn,Katherine L. Nathanson,Alan Alan Diehl

DOI: https://doi.org/10.1128/MCB.00706-13

IF: 5.069

2013-01-01

Molecular and Cellular Biology

Abstract:Cyclin D1-cyclin-dependent kinase 4/6 (CDK4/6) dysregulation is a major contributor to melanomagenesis. Clinical evidence has revealed that p16(INK4A), an allosteric inhibitor of CDK4/6, is inactivated in over half of human melanomas, and numerous animal models have demonstrated that p16INK4A deletion promotes melanoma. FBXO4, a specificity factor for the E3 ligase that directs timely cyclin D1 proteolysis, has not been studied in melanoma. We demonstrate that Fbxo4 deficiency induces Braf-driven melanoma and that this phenotype depends on cyclin D1 accumulation in mice, underscoring the importance of this ubiquitin ligase in tumor suppression. Furthermore, we have identified a substrate-binding mutation, FBXO4 I377M, that selectively disrupts cyclin D1 degradation while preserving proteolysis of the other known FBXO4 substrate, TRF1. The I377M mutation and Fbxo4 deficiency result in nuclear accumulation of cyclin D1, a key transforming neoplastic event. Collectively, these data provide evidence that FBXO4 dysfunction, as a mechanism for cyclin D1 overexpression, is a contributor to human malignancy.